Cheah Seong Keat, Halsall David, Barker Peter, Grant John, Mathews Abraham, Seshadri Shyam, Krishnan Singhan
Endocrinology Department, Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, UK.
Pathology Department, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Endocrinol Diabetes Metab Case Rep. 2018 Sep 24;2018:EDM18-0049. doi: 10.1530/EDM-18-0049.
A frail 79-year-old lady with dementia presented with a 2-year history of frequent falls. Recurrent hypoglycaemic episodes were diagnosed and treated with continuous glucose infusion in multiple hospital admissions. Hypoadrenalism and hypothyroidism were ruled out. Whilst hypoglycaemic (blood glucose 1.6 mmol/L), both plasma C-peptide and proinsulin concentrations, were inappropriately elevated at 4210 pmol/L (174–960) and >200 pmol/L (0–7) respectively with plasma insulin suppressed at 12 pmol/L (0–180). Whilst reported cases of proinsulinoma are typically pancreatic in origin, radiological investigations of the pancreas in this patient did not identify abnormalities. Unexpectedly contrast CT identified a heterogeneously enhancing mass (6.6 cm) at the lower pole of the left kidney consistent with renal cell carcinoma. Non-islet cell tumour-induced hypoglycaemia has been associated with renal malignancy; however, a serum IGF2:IGF1 ratio measured at <10 effectively excludes this diagnosis. Concomitantly on the CT, extensive peripherally enhancing heterogeneous mass lesions in the liver were identified, the largest measuring 12 cm. A palliative approach was taken due to multiple comorbidities. On post-mortem, the kidney lesion was confirmed as clear cell renal carcinoma, whilst the liver lesions were identified as proinsulin-secreting neuroendocrine tumours. In conclusion, the diagnosis of proinsulinoma can be missed if plasma proinsulin concentration is not measured at the time of hypoglycaemia. In this case, the plasma insulin:C-peptide ratio was too high to be accounted for by the faster relative clearance of insulin and was due to proinsulin cross-reactivity in the C-peptide assay. In addition, the concomitant malignancy proved to be a challenging red herring. Learning points: •• Even in non-diabetics, hypoglycaemia needs to be excluded in a setting of frequent falls. Insulin- or proinsulinsecreting tumours are potentially curable causes. •• Whilst investigating spontaneous hypoglycaemia, if plasma insulin concentration is appropriate for the hypoglycaemia, it is prudent to check proinsulin concentrations during the hypoglycaemic episode. •• Proinsulin cross-reacts variably with C-peptide and insulin assays; the effect is method dependent. In this case, the discrepancy between the insulin and C-peptide concentrations was too great to be accounted for by the faster relative clearance of insulin, raising the suspicion of assay interference. The C-peptide assay in question (Diasorin liaison) has been shown to be 100% cross reactive with proinsulin based on spiking studies with a proinsulin reference preparation. •• Whilst reported cases of proinsulinoma and 99% of insulinomas are of pancreatic origin, conventional imaging studies (CT, MRI or ultrasound) fail to detect neuroendocrine tumours <1 cm in 50% of cases. •• The concomitant renal mass identified radiologically proved to be a red herring. •• In view of the rarity of proinsulinoma, no conclusive association with renal cell carcinoma can be established.
一位79岁的体弱痴呆女性患者,有2年频繁跌倒病史。多次住院时诊断为反复低血糖发作,并通过持续输注葡萄糖进行治疗。排除了肾上腺皮质功能减退症和甲状腺功能减退症。在低血糖时(血糖1.6 mmol/L),血浆C肽和胰岛素原浓度分别不恰当地升高至4210 pmol/L(174 - 960)和>200 pmol/L(0 - 7),而血浆胰岛素被抑制在12 pmol/L(0 - 180)。虽然报道的胰岛素瘤病例通常起源于胰腺,但该患者胰腺的影像学检查未发现异常。意外的是,增强CT在左肾下极发现一个不均匀强化的肿块(6.6 cm),符合肾细胞癌。非胰岛细胞瘤所致低血糖与肾恶性肿瘤有关;然而,血清IGF2:IGF1比值<10可有效排除该诊断。同时在CT上,肝脏发现广泛的周边强化不均匀肿块病变,最大的为12 cm。由于多种合并症,采取了姑息治疗方法。尸检时,肾脏病变确诊为透明细胞肾细胞癌,而肝脏病变被确定为分泌胰岛素原的神经内分泌肿瘤。总之,如果在低血糖时未检测血浆胰岛素原浓度,可能会漏诊胰岛素瘤。在本病例中,血浆胰岛素:C肽比值过高,不能用胰岛素相对清除较快来解释,而是由于C肽检测中胰岛素原的交叉反应。此外,同时存在的恶性肿瘤被证明是一个具有挑战性的干扰因素。学习要点:••即使在非糖尿病患者中,频繁跌倒情况下也需要排除低血糖。胰岛素或胰岛素原分泌肿瘤是潜在可治愈的病因。••在调查自发性低血糖时,如果血浆胰岛素浓度与低血糖情况相符,在低血糖发作期间检查胰岛素原浓度是谨慎的做法。••胰岛素原与C肽和胰岛素检测的交叉反应各不相同;其影响取决于检测方法。在本病例中,胰岛素和C肽浓度之间的差异太大,不能用胰岛素相对清除较快来解释,这引起了对检测干扰的怀疑。所讨论的C肽检测方法(DiaSorin Liaison)基于用胰岛素原参考制剂进行的加样研究,已显示与胰岛素原100%交叉反应。••虽然报道的胰岛素瘤病例和99%的胰岛素瘤起源于胰腺,但传统影像学检查(CT、MRI或超声)在50%的病例中无法检测到<1 cm的神经内分泌肿瘤。••影像学检查发现的同时存在的肾脏肿块被证明是一个干扰因素。••鉴于胰岛素瘤的罕见性,无法确定其与肾细胞癌的确切关联。